Study to determine bioavailablity of 300 mg aliskiren mini-tablets vs 300 mg aliskiren market tablet. - Trial 2012-000855-15

Name: Clinical Trial 2012-000855-15
Creator: Novartis Pharma Services AG
Keywords: Hypertension, clinical trial

Access comprehensive clinical trial information for 2012-000855-15 through Pure Global AI's free database. This phase not specified trial is sponsored by Novartis Pharma Services AG and is currently status unknown. The study focuses on Hypertension.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to EU Clinical Trials Register data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database

840K+ Trials

2012-000855-15

Trial Details

EU Clinical Trials Register • 2012-000855-15

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing

Study to determine bioavailablity of 300 mg aliskiren mini-tablets vs 300 mg aliskiren market tablet.

Study Focus

Disease/Condition

Hypertension

Sponsor & Location

Primary Sponsor

Novartis Pharma Services AG

Timeline & Enrollment

Phase

N/A

Start Date

N/A

End Date

N/A

Primary Outcome

- Use of any prescription drugs, herbal supplements, within four (4) weeks prior to initial dosing, and/or over-the-counter (OTC) medication, dietary supplements (vitamins included) within two (2) weeks prior to initial dosing.

ICD-10 Classifications

Hypertensive diseases

Renovascular hypertension

Secondary hypertension

Other secondary hypertension

Hypertensive heart disease

Data Source

Registry

EU Clinical Trials Register

Trial ID

2012-000855-15

Type

Non-Device Trial